Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Debt (2019 - 2025)

OptimizeRx (OPRX) has disclosed Total Debt for 5 consecutive years, with $25.7 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 21.76% to $25.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.7 million through Dec 2025, down 21.76% year-over-year, with the annual reading at $25.7 million for FY2025, 21.76% down from the prior year.
  • Total Debt hit $25.7 million in Q4 2025 for OptimizeRx, down from $28.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $36.2 million in Q4 2023 to a low of $25.7 million in Q4 2025.
  • Historically, Total Debt has averaged $32.3 million across 3 years, with a median of $32.8 million in 2024.
  • Biggest five-year swings in Total Debt: dropped 9.43% in 2024 and later fell 21.76% in 2025.
  • Year by year, Total Debt stood at $36.2 million in 2023, then decreased by 9.43% to $32.8 million in 2024, then fell by 21.76% to $25.7 million in 2025.
  • Business Quant data shows Total Debt for OPRX at $25.7 million in Q4 2025, $28.1 million in Q3 2025, and $28.4 million in Q2 2025.